Article
Development and clinical validity of a novel blood-based molecular biomarker for subclinical acute rejection following kidney transplant.
American journal of transplantation : official journal of the American Society of Transplantation and the American Society of Transplant Surgeons - 1 Jan 2019
Friedewald John J, Kurian Sunil M, Heilman Raymond L, Whisenant Thomas C, Poggio Emilio D, Marsh Christopher, Baliga Prabhakar, Odim Jonah, Brown Merideth M, Ikle David N, Armstrong Brian D, Charette Jane I, Brietigam Susan S, Sustento-Reodica Nedjema, Zhao Lihui, Kandpal Manoj, Salomon Daniel R, Abecassis Michael M
Abstract excerpt
Noninvasive biomarkers are needed to monitor stable patients after kidney transplant (KT), because subclinical acute rejection (subAR), currently detectable only with surveillance biopsies, can lead to chronic rejection and graft loss. We conducted a multicenter study to develop a blood-based molecular biomarker for subAR using peripheral blood paired with surveillance biopsies and strict clinical phenotyping...
Read the complete abstract on PubMedTopics
Share this publication in a Topic to start or enrich a Post.
